MARKET NEWS

Denali Therapeutics Announces Completion of Enrollment for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial
Next-Generation RNA Company Launched by Argobio & University of Southern Denmark
MBX Biosciences Announces Positive Phase 1 Topline Results for Post-Bariatric Hypoglycemia Treatment
RESTEM Receives FDA Fast Track Designation for Restem-L for Idiopathic Inflammatory Myopathy
FDA Accepts Final Protocol for Pivotal Phase 3 Alzheimer’s Disease Study, Streamlining Development Pathway
QUANTRO Therapeutics Achieves Breakthrough in Transcriptomic Drug Discovery
Phillips Medisize Expands Its Inhalation Drug Delivery Capabilities
Fortress Biotech & Cyprium Therapeutics Announce FDA Acceptance & Priority Review of NDA for CUTX-101 for Treatment of Menkes Disease
Nuvation Bio Receives Approval from China’s National Medical Products Administration for Taletrectinib for Patients with Advanced ROS1-Positive Non-Small Cell Lung Cancer
Atavistik Bio Announces Research Collaboration With Pfizer

  EXPERT CONTENT & RESOURCES

CLINICAL TRIALS - Need for Accessibility to Meet FDA Guidance for Decentralized Trials

CLINICAL TRIALS - Need for Accessibility to Meet FDA Guidance for Decentralized Trials

Neil Vivian believes advances in electronic data collection and analysis are helping to make DCTs more accessible to broader and more diverse patient populations. Further innovations, particularly in artificial intelligence technology, are expected to accelerate these trends.  

MediWound Ltd.:  Developing a New Class of Biologic Enzymatic Therapeutic  Products to Debride Wounds

MediWound Ltd.:  Developing a New Class of Biologic Enzymatic Therapeutic  Products to Debride Wounds

Drug Development & Delivery recently interviewed Ofer Gonen, Chief Executive Officer of MediWound, to discuss the company’s innovative approach to debridement.

BASF Article - Should Developers Choose a Cosmetic or Pharmaceutical-Grade Excipient?

BASF Article - Should Developers Choose a Cosmetic or Pharmaceutical-Grade Excipient?

As regulations continue to change around cosmetic and pharmaceutical-grade excipients, the pharmaceutical industry has choices to make when investing in quality, risk, and public safety.

  FEATURED EDITORIAL

  COMPANY PROFILE

Abzena is the leading end-to-end CDMO + CRO for bioconjugates, ADCs and complex biologics. From discovery through commercial launch, we support customers with fully integrated programs or individual services designed to de-risk and streamline the development of new treatments for patients in need. With the ability to tailor our strategy and customer experience to each project, Abzena develops and implements innovative solutions that enable biotech and biopharma companies to realize the full potential of their molecule. Click here for more.

  WHITEPAPERS & WEBINARS

WEBINAR: Introducing Key Concepts in Tableting Research: Unleashing Essential Concepts and Strategies for Enhanced Formulation Development

WEBINAR: Introducing Key Concepts in Tableting Research: Unleashing Essential Concepts and Strategies for Enhanced Formulation Development

Tableting can present a series of challenges, particularly when dealing with formulations that have poor flowability, low compressibility, or high cohesivity. These issues can lead to manufacturing inefficiencies….

  WHITEPAPERS & WEBINARS

WHITEPAPER - Unlock the Secrets of Spray Drying for Sticky APIs

WHITEPAPER - Unlock the Secrets of Spray Drying for Sticky APIs

It is widely reported that 40% of New Chemical Entities (NCEs) in the pharmaceutical industry are poorly soluble, leading to inadequate bioavailablity. Spray drying is one of the most promising particle engineering technologies used to overcome solubility issues in active …

ARTICLE - A New Framework for Identifying Nitrosamine Risks & Efficiently Derisking Products

ARTICLE - A New Framework for Identifying Nitrosamine Risks & Efficiently Derisking Products

A clear standard for identifying APIs susceptible to Nitrosamine Drug Substance-Related Impurities (NDSRI) formation has been elusive—until now. Adare’s team of nitrosamine experts have developed a straightforward framework that simplifies the identification of at-risk APIs. Discover how this innovative approach …

CASE STUDY - Overcoming Barriers to Patient Adherence With A Novel Dosage Form

CASE STUDY - Overcoming Barriers to Patient Adherence With A Novel Dosage Form

When a mid-sized pharmaceutical company asked Adare to make a version of their drug that was more convenient for patients with tremors or swallowing difficulties, our experts created a sprinkle formulation of the drug. In this CPHI Award-winning case study, …

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

January 15 – Excipients
January 29 – Bioavailability